Related Experiment Video

Updated: Mar 5, 2026

Mapping the Structure-Function Relationships of Disordered Oncogenic Transcription Factors Using Transcriptomic Analysis
09:58

Mapping the Structure-Function Relationships of Disordered Oncogenic Transcription Factors Using Transcriptomic Analysis

Published on: June 27, 2020

3.2K

A recurrent endometrial stromal sarcoma harbors the novel fusion JAZF1-BCORL1

Allison J Allen1, Siraj M Ali2, Kyle Gowen2

  • 1Department of Obstetrics and Gynecology and the Knight Cancer Institute, Oregon Health & Science University, Portland, OR, United States.

Gynecologic Oncology Reports
|March 24, 2017
PubMed

Insights

Genomic alterations in endometrial stromal sarcoma can enhance diagnosis and treatment. A new JAZF1-BCORL1 mutation offers potential for targeted therapies to improve patient survival.

Area of Science:

  • Oncology
  • Genetics
  • Molecular Biology

Background:

  • Endometrial stromal sarcoma (ESS) is a rare uterine malignancy.
  • Accurate diagnosis and effective treatment strategies are crucial for patient outcomes.
  • Genomic profiling is increasingly recognized for its role in cancer management.

Observation:

  • Genomic alterations in ESS can significantly impact diagnostic accuracy.
  • A novel JAZF1-BCORL1 gene fusion mutation was identified in ESS.
  • This specific mutation may serve as a diagnostic biomarker.

Findings:

  • Identification of the JAZF1-BCORL1 mutation provides a new molecular target.
  • Understanding genomic alterations refines the classification of ESS.
  • This discovery opens avenues for personalized medicine approaches.

Implications:

  • Genomic insights can lead to improved diagnostic certainty for endometrial stromal sarcoma.
  • Targeted therapies directed at downstream effectors of the JAZF1-BCORL1 pathway may enhance treatment efficacy.
  • These advancements hold the potential to improve survival benefits for patients with ESS.
Keywords:
ChromatinEndometrial stromal sarcomaJAZF1Polycomb

More Related Videos

Modeling Osteosarcoma Using Li-Fraumeni Syndrome Patient-derived Induced Pluripotent Stem Cells08:52

Modeling Osteosarcoma Using Li-Fraumeni Syndrome Patient-derived Induced Pluripotent Stem Cells

Published on: June 13, 2018

9.4K
Ortho- and Ectopic Zebrafish Xeno-Engraftment of Ocular Melanoma to Recapitulate Primary Tumor and Experimental Metastasis Development06:46

Ortho- and Ectopic Zebrafish Xeno-Engraftment of Ocular Melanoma to Recapitulate Primary Tumor and Experimental Metastasis Development

Published on: September 4, 2021

1.9K

Related Concept Videos

The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
4.9K
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
6.5K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
Metastasis02:30

Metastasis

Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
6.7K
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.6K